Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Welcome and Introduction to Vi3C

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Oct
25
Today In Oncology
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sezary Syndrome
FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors
Geographic Distribution of Triple-Negative Breast Cancer Clinical Trials
Financial Incentives Increase Smoking Abstinence Among Those Referred for Lung Cancer Screening
Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo